A Rare Cause of Uptake of Radioactive Iodine by  Non-Lactating Breast Tissue in A Patient with  Papillary Thyroid Carcinoma: Prolactinoma

Zeynel Abidin Sayıner; Umut Elboğa; Azer Abiyev; Mesut Özkaya; Ersin Akarsu

doi:10.5152/EurJTher.2018.289

Authors

Zeynel Abidin Sayıner Division of Endocrinology and Metabolism, Gaziantep Unıversity, School of Medicine, Gaziantep https://orcid.org/0000-0001-5105-0292
Umut Elboğa Department of Nuclear Medicine, Gaziantep Unıversity, School of Medicine, Gaziantep https://orcid.org/0000-0002-3650-8258
Azer Abiyev Department of Internal Medicine, Gaziantep Unıversity, School of Medicine, Gaziantep https://orcid.org/0000-0003-2962-6800
Mesut Özkaya Division of Endocrinology and Metabolism, Gaziantep Unıversity, School of Medicine, Gaziantep https://orcid.org/0000-0003-2616-5885
Ersin Akarsu Division of Endocrinology and Metabolism, Gaziantep Unıversity, School of Medicine, Gaziantep https://orcid.org/0000-0003-2786-6616

DOI:

https://doi.org/10.5152/EurJTher.2018.289

Keywords:

Papillar thyroid cancer, prolactinoma, uptake of radioactive iodine

Abstract

We report a case of a post-menopausal woman who underwent total thyroidectomy due to papillary thyroid carcinoma followed by radioactive iodine therapy. After radioactive iodine therapy, total body scintigraphy (TBS) using radioactive iodine (I-131) was performed, and we observed uptake of I-131 by breast tissues. The scintigraphic and associated clinical characteristics of uptake of I-131 by breast tissues in a non-breastfeeding patient with thyroid cancer were unexpected findings. In this patient, elevated serum prolactin levels were documented at the time when the uptake of I-131 by the breast tissues was observed. We conducted hypophysis magnetic resonance imaging and detected a pituitary adenoma. Medical treatment with cabergoline was provided to this patient. When prolactin levels were normalized, uptake of I-131 by breast tissues was no longer evident on TBS.

Metrics

Metrics Loading ...

References

Allen T, Wiest P, Vela S, Hartshorne M, Crooks LA. I-131 uptake in the breast for thyroid cancer surveillance with biopsy-proven benign tissue. Clin Nucl Med 1998; 23: 585-7.

Ronga G, Bruno R, Puxeddu E, Calcinaro F, Montesano T, Travascio L, et al. Radioiodineuptake in non lactating mammary glands: evidence for a causative role of hyperprolactinemia. Thyroid 2007; 17: 363-6.

Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, et al. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 1998; 83: 2493-6.

Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 2000; 6: 871-8.

Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997; 138: 5555 60.

Rillema JA, Collins S, Williams CH. Prolactin stimulation of iodide uptake and incorporation into protein is polyamine-dependent in mouse mammary gland explants. Proc Soc Exp Biol Med 2000; 224: 41-4.

Bruno R, Giannasio P, Ronga G, Baudin E, Travagli JP, Russo D, et al. Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. J Endocrinol Invest 2004; 27: 1010-4.

David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22: 1085-96.

Cowden EA, Ratcliffe WA, Ratcliffe JG, Dobbie JW, Kennedy AC. Hyperprolactinaemia in renal disease. Clin Endocrinol (Oxf) 1978; 9: 241-8.

Peces R, Casado S, Frutos M, Horcajada C, López-Novoa JM, Hernando L. Prolactin in chronic renal failure, haemodialysis, and transplant patients. Proc Eur Dial Transplant Assoc 1979; 16: 700-2.

Ahn JH, Kim SY, Kim YJ, Lee SY, Lee JH, Kang SH, et al. Hyperprolactinemia-Associated Breast Uptake of Radioiodine Following 131I Postablation Scan in Differentiated Thyroid Cancer. Endocrinol Metab 2011; 26: 345-7.